Use Of HIV-Prevention Drug Grows, But Lags Among Non-Whites
The pill, known as PrEP, can reduce the risk of contracting the virus that causes AIDS by 90 percent. Its use has expanded sharply in recent years — but primarily among a white demographic.
Drugs
1,001 - 1,020 of 1,288 Results
-
-
Opioid Maker Funds Efforts To Fight Addiction: Is It ‘Blood Money’ Or Charity?
Purdue Pharma, whose signature product helped fuel the opioid epidemic, now wants to help treat it — or at least salvage its own reputation.
By Jenny Gold -
Lifting Therapy Caps Is A Load Off Medicare Patients’ Shoulders
Last month’s budget deal means Medicare beneficiaries are eligible for physical and occupational therapy indefinitely. Plus, prescription drug costs will fall for more seniors.
By Susan Jaffe -
Patients Overpay For Prescriptions 23% Of The Time, Analysis Shows
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
-
A Battered Doctor, A Slain Patient And A Family’s Quest For Answers
An addiction-treatment physician fatally shot a troubled ex-Marine after the man pummeled him inside his California office, police records show. The tragedy illustrates how the limited number of clinics available to prescribe buprenorphine, a drug that all but erases opioid withdrawal, can become crowded, chaotic and dangerous.
By Brian Rinker -
Black Men’s Blood Pressure Is Cut Along With Their Hair
A new study shows that educational sessions about high blood pressure at African American barbershops, coupled with prescribing and helping to manage medication, reduced hypertension rates significantly.
By Susan Abram -
Rising Health Costs, Soaring Drug Prices, Confusing Bills! What’s A Consumer To Do?
KHN correspondent Shefali Luthra answered a wide variety of questions about health care in a Reddit “Ask Me Anything” chat.
-
Campus Voices: Should Student Health Centers Offer Abortion Pills?
California lawmakers are considering a bill that would require student health centers at all of the state’s four-year public universities to carry the abortion pill. Students at campuses across the state sounded off on the proposal.
By Ana B. Ibarra and Anna Gorman -
Podcast: KHN’s ‘What The Health?’ HHS Leaders Take To The Stump
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
-
Of ‘Miracles’ And Money: Why Hemophilia Drugs Are So Expensive
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
By Jenny Gold -
Jury’s In: Opioids Are Not Better Than Other Medicines For Chronic Pain
A new study followed patients with severe chronic pain for a year and found that opioids relieved pain and increased function no better than common drugs like acetaminophen and lidocaine. But the opioids carry the risk of more serious side effects, including addiction and death.
-
States Strive To Curb Costs For A Crucial — But Exorbitant — Hemophilia Treatment
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
-
Cartoon Mascot Masks Nasty Health Care Feud
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
-
In An Effort To Curb Drug Costs, States Advance Bills To Prod Feds On Importation
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
-
FDA Head Vows To Tackle High Drug Prices And Drugmakers ‘Gaming The System’
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
By Sarah Jane Tribble and Liz Szabo -
Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
-
KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR's Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
-
Podcast: KHN’s ‘What The Health?’ There’s A Really Big Health Bill In That Budget Deal
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”
-
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
By Jay Hancock and Shefali Luthra -
Podcast: KHN’s ‘What The Health?’ The State Of The (Health) Union
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.